Navigation Links
Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target

WELWYN GARDEN CITY, England, October 12 /PRNewswire/ --

- Terms Include up to $200 million in Potential Fees and Milestones Plus Royalties

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis. The agreement includes upfront and potential milestone payments to Heptares totaling up to $200 million plus royalties. Full financial terms were not disclosed.

StaR technology enables GPCRs, normally membrane-bound, to be worked on in solution, allowing the use of structure-based drug discovery technologies and the discovery of novel drugs addressing this important set of targets. Heptares is deploying this technology principally to generate small molecule drugs against currently difficult or intractable GPCR targets in several disease areas.

Under the terms of the agreement with the Novartis Option Fund, Heptares will apply its StaR technology to a target identified by Novartis and drive a drug discovery programme against that target.

"This is an excellent early deal for Heptares, endorsing our StaR technology and further strengthening our financial position," said Malcolm Weir, CEO of Heptares Therapeutics. "The deal with the Novartis Option Fund demonstrates confidence that our approach can unlock the potential of GCPR targets and forms a solid foundation for other partnerships with leading pharmaceutical companies."

"The potential of GPCRs as targets for drug discovery is well recognized, but it has always been a challenge to gain structural information on GPCRs," said Anja Koenig for the Novartis Option Fund. "We believe that the power of Heptares' technology to resolve GPCR structures and their expertise in small molecule chemistry will lead to rapid progress in the drug discovery programme against Novartis' nominated target."

The Novartis Option Fund invested GBP7 million in Heptares' GBP21 million fundraising announced in February 2009 in a syndicate with MVM Life Science Partners and Clarus Ventures.

About Heptares Therapeutics Ltd

Heptares is a drug discovery company focused on identifying novel drug candidates targeting validated G-protein-coupled receptors (GPCRs) in several disease areas. Based on its unique StaR(TM) technology platform, Heptares has built an integrated drug discovery capability and aims to progress promising candidates internally and through strategic alliances.

GPCRs are the single most important family of drug targets in the human body, but because of their inherent instability they are refractory to structural studies and biochemical screening. StaR technology enables the engineering of stabilised GPCRs, making them amenable to these vital drug discovery approaches. There are many clinically relevant GPCR targets across a wide range of therapeutic areas where discovery is advancing slowly and for which structural information, novel screening approaches and potential antibody therapeutics would greatly enhance progress.

Heptares was founded in 2007 and its StaR technology arose out of the pioneering work of Heptares' founding scientists at the MRC Laboratory of Molecular Biology (Cambridge, UK) and the National Institute for Medical Research (London, UK).

For more information, see

About the Novartis Option Fund

The Novartis Option Fund is a $200 million fund that is part of the Novartis Venture Funds. Established in 1996, the Novartis Venture Funds currently manage over $750 million in committed capital and is invested in more than 50 private companies. The objective of the Novartis Option Fund is to seed innovative companies through initial and follow on investments. The initial investment is coupled with an option to a specific therapeutic program providing early validation for the company's technology by a larger pharmaceutical partner. The Novartis Venture Funds' team of eight investment professionals located in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in the biotech and pharmaceutical industry and venture capital.

    For more information:

    Contact Information:

    Heptares Therapeutics Ltd
    Dr Malcolm Weir
    Phone:  +44(0)1707-358-629
    Mobile: +44(0)7968-947268

    Citigate Dewe Rogerson
    Dr Mark Swallow, Dr Chris Gardner
    Phone: +44(0)20-7282-2948

SOURCE Heptares Therapeutics Ltd

SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
2. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
3. Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
4. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
5. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
6. Reportlinker Adds Stem Cell Therapeutics Markets Report
7. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
8. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
9. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
10. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... This ... entrepreneurs at competitive events in five states to develop and pitch their BIG ideas ... projects from each state are competing for votes to win the title of SAP's ...
(Date:11/24/2015)... November 24, 2015 --> ... research report released by Transparency Market Research, the global ... a CAGR of 17.5% during the period between 2014 ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends ... prenatal testing market to reach a valuation of US$2.38 ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):